col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Elsevier: Journal of Substance Abuse Treatment
  original article Date Title Authors   All Authors
1 [GO] 2021―Jul―21 SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups Peter J. Kelly, Kim McCreanor, Alison K. Beck, Isabella Ingram, Darren O'Brien, Angie King, et al. (+9)
2 [GO] 2021―Jun―26 The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth Richard H. Cales, Shannon C. Cales, Jacob Shreffler, Martin R. Huecker
3 [GO] 2021―Jun―25 COVID-19 related substance use services policy changes: Policymaker perspectives on policy development & implementation Brandy F. Henry, Aimee Campbell, Timothy Hunt, Jessica K. Johnson, Amar D. Mandavia, Michael Chaple, et al. (+7)
4 [GO] 2021―Jun―24 Changes in methadone take-home dosing before and after COVID-19 Ofer Amram, Solmaz Amiri, Emily L. Thorn, Robert Lutz, Paul J. Joudrey
5 [GO] 2021―Jun―24 The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives Chunqing Lin, Sarah E. Clingan, Sarah J. Cousins, Jonathan Valdez, Larissa J. Mooney, Yih-Ing Hser
6 [GO] 2021―May―31 Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms Peter C. Treitler, Cadence F. Bowden, James Lloyd, Michael Enich, Amesika Nyaku, Stephen Crystal
7 [GO] 2021―May―18 Corrigendum to “Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study” [Journal of Substance Abuse Treatment 129 (2021) 108374] Cayley Russell, Farihah Ali, Frishta Nafeh, Jürgen Rehm, Sean LeBlanc, Tara Elton-Marshall
8 [GO] 2021―Apr―29 Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19 Sarah Brothers, Adam Viera, Robert Heimer
9 [GO] 2021―Apr―29 Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects Bradley M. Buchheit, Haven Wheelock, Abby Lee, Kimberly Brandt, Jessica Gregg
10 [GO] 2021―Apr―09 The new services that opioid treatment programs have adopted in response to COVID-19 Jonathan Cantor, Agustina Laurito
11 [GO] 2021―Apr―09 The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here? Kathlene Tracy, Leah Wachtel, Teri Friedman
12 [GO] 2021―Apr―09 How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic Jesse M. Pines, Mark S. Zocchi, Bernard S. Black, Jestin N. Carlson, Pablo Celedon, Ali Moghtaderi, Arvind Venkat
13 [GO] 2021―Apr―08 Adaptations to Indiana's 21st Century Cures-funded recovery coaching initiative in the wake of COVID-19 Monte D. Staton, Dennis P. Watson, Lisa Robison Taylor, Noah Tye
14 [GO] 2021―Apr―08 Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder Colleen B. Mistler, Matthew C. Sullivan, Michael M. Copenhaver, Jaimie P. Meyer, Alexis M. Roth, Sheela V. Shenoi, et al. (+3)
15 [GO] 2021―Apr―08 Impact of COVID-19 on service delivery for an evidence-based behavioral treatment for families involved in the child welfare system Gracelyn Cruden, Mark Campbell, Lisa Saldana
16 [GO] 2021―Apr―08 Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic Jonathan Cantor, Andrew W. Dick, Rebecca Haffajee, Megan F. Pera, Dena M. Bravata, Bradley D. Stein, Christopher Whaley
17 [GO] 2021―Apr―08 Research on substance use disorders during the COVID-19 pandemic Nora D. Volkow, Carlos Blanco
18 [GO] 2021―Mar―23 Addressing cigarette smoking cessation treatment challenges during the COVID-19 pandemic with social media Meredith C. Meacham, Erin A. Vogel, Johannes Thrul, Danielle E. Ramo, Derek D. Satre
19 [GO] 2021―Mar―20 Identifying the Impacts of the COVID-19 Pandemic on Service Access for People who Use Drugs (PWUD): A National Qualitative Study Cayley Russell, Farihah Ali, Frishta Nafeh, Jürgen Rehm, Sean LeBlanc, Tara Elton-Marshall
20 [GO] 2021―Mar―20 Recovering from substance use disorder during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City Emily A. Hurley, Kimberly Piña, Victoria Cegielski, Janelle R. Noel-MacDonnell, Melissa K. Miller
21 [GO] 2021―Feb―11 Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic Michael Kidorf, Robert K. Brooner, Kelly E. Dunn, Jessica M. Peirce
22 [GO] 2021―Jan―26 Telemedicine works for treating substance use disorder: The STAR clinic experience during COVID-19 Leah Fiacco, Brenda L. Pearson, Robyn Jordan
23 [GO] 2021―Jan―20 Using Telehealth to Improve Buprenorphine Access During and After COVID-19: A Rapid Response Initiative in Rhode Island Seth A. Clark, Elizabeth A. Samuels, Rachel S. Wightman, Caroline Wunsch, Lee Ann Jordison Keeler, Neha Reddy, Corey Davis
24 [GO] 2021―Jan―18 Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic Linda Wang, Jeffrey Weiss, Elizabeth Bogel Ryan, Justine Waldman, Stacey Rubin, Judy L. Griffin
25 [GO] 2021―Jan―13 Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study Sarah B. Hunter, Alex R. Dopp, Allison J. Ober, Lori Uscher-Pines
26 [GO] 2021―Jan―08 Adaptations to substance use disorder monitoring by physician health programs in response to COVID-19 Alexis Polles, Christopher Bundy, William Jacobs, Lisa J. Merlo
27 [GO] 2021―Jan―08 Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19 Mary C. Figgatt, Zach Salazar, Elizabeth Day, Louise Vincent, Nabarun Dasgupta
28 [GO] 2021―Jan―08 A Collision of Crises: Addressing an HIV Outbreak among People who Inject Drugs in the midst of COVID-19 Jessica L. Taylor, Glorimar Ruiz-Mercado, Heather Sperring, Angela R. Bazzi
29 [GO] 2021―Jan―08 Increased HIV testing in people who use drugs hospitalized in the first wave of the COVID-19 pandemic Julia Zubiago, Meghan Murphy, Rubeen Guardado, Denise Daudelin, Dustin Patil, Alysse Wurcel
30 [GO] 2021―Jan―02 Integrated substance use and prenatal care delivery in the era of COVID-19 Elizabeth W. Patton, Kelley Saia, Michael D. Stein
31 [GO] 2020―Dec―28 Substance use treatment in Appalachian Tennessee amid COVID-19: Challenges and preparing for the future Satish K. Kedia, Michael Schmidt, Patrick J. Dillon, Hassan Arshad, Xinhua Yu
32 [GO] 2020―Dec―27 Sharp Decline in Hospital and Emergency Department Initiated Buprenorphine for Opioid Use Disorder During COVID-19 State of Emergency in California Andrew A. Herring, Mariah Kalmin, Melissa Speener, David Goodman-Meza, Hannah Snyder, Arianna Sampson, et al. (+2)
33 [GO] 2020―Dec―27 Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder Kristi Lynn Stringer, Kirsten J. Langdon, Michelle McKenzie, Brad Brockmann, Phillip Marotta
34 [GO] 2020―Dec―17 Impacts of COVID-19 on residential treatment programs for substance use disorder A. Pagano, S. Hosakote, K. Kapiteni, E. Straus, J. Wong, J. Guydish
35 [GO] 2020―Dec―13 A chance to do it better: Methadone maintenance treatment in the age of Covid-19 David Frank
36 [GO] 2020―Dec―11 Addressing a rapidly changing service landscape during the COVID-19 pandemic: Creation of the Oregon substance use disorder resource collaborative Rachel A. Lockard, Kelsey C. Priest, Patrick C.M. Brown, Amanda Graveson, Honora Englander
37 [GO] 2020―Dec―11 COVID-19 surveillance and Black American substance use disorder: An examination of data and policy Vanessa Miller
38 [GO] 2020―Dec―05 Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives Mary A. Hatch-Maillette, K. Michelle Peavy, Judith I. Tsui, Caleb J. Banta-Green, Stephen Woolworth, Paul Grekin
39 [GO] 2020―Dec―04 With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic Matthew W. Courser, Holly Raffle
40 [GO] 2020―Dec―03 Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19 Giliane Joseph, Kristine Torres-Lockhart, Melissa R. Stein, Pamela Mund, Shadi Nahvi
41 [GO] 2020―Dec―03 Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19 Nicholas A. Livingston, Victoria Ameral, Anne N. Banducci, Risa B. Weisberg
42 [GO] 2020―Dec―03 Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges Shalini Arunogiri, Nicholas Lintzeris
43 [GO] 2020―Dec―03 Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response Amy McDonnell, Courtney MacNeill, Brittany Chapman, Nicole Gilbertson, Megan Reinhardt, Stephanie Carreiro
44 [GO] 2020―Dec―03 COVID-19: Broadening the horizons of U.S. harm reduction practices through managed alcohol programs Nicky J. Mehtani, Jessica T. Ristau, Joanna Eveland
45 [GO] 2020―Dec―02 The use of mindfulness dialogue for life in substance use disorder treatment in the time of COVID-19 Diane J. Abatemarco, Meghan Gannon, Dennis J. Hand, Vanessa L. Short, Kimberly McLaughlin, Daniel Martin
46 [GO] 2020―Dec―02 COVID-19 and treating incarcerated populations for opioid use disorder Christopher J. Donelan, Edmond Hayes, Ruth A. Potee, Levin Schwartz, Elizabeth A. Evans
47 [GO] 2020―Nov―24 A delicate compromise: Striking a balance between public safety measures and the psychosocial needs of staff and clients in residential substance use disorder treatment amid COVID-19 Ashleigh Herrera
48 [GO] 2020―Nov―24 Adolescent substance use: Challenges and opportunities related to COVID-19 Dana Sarvey, Justine W. Welsh
49 [GO] 2020―Nov―24 Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19 Max Jordan Nguemeni Tiako
50 [GO] 2020―Nov―24 Telehealth sustains patient engagement in OUD treatment during COVID-19 James R. Langabeer, Andrea Yatsco, Tiffany Champagne-Langabeer
51 [GO] 2020―Nov―24 Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic Kelly E. Dunn, Robert K. Brooner, Kenneth B. Stoller
52 [GO] 2020―Nov―22 Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders Sara J. Becker, Bryan R. Garner, Bryan J. Hartzler
53 [GO] 2020―Nov―21 Socially distant and out of reach: Unintended consequences of COVID-19 prevention efforts on transgender and gender non-binary populations in Puerto Rico Kyle Melin, Darlene Santiago Quiñones, Carlos E. Rodríguez-Díaz
54 [GO] 2020―Nov―17 Caring for women with substance use disorders through pregnancy and postpartum during the COVID-19 pandemic: Lessons learned from psychology trainees in an integrated OBGYN/substance use disorder outpatient treatment program Jaclyn S. Sadicario, Anna Beth Parlier-Ahmad, Julia K. Brechbiel, Leila Z. Islam, Caitlin E. Martin
55 [GO] 2020―Nov―14 Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade? Edward V. Nunes, Frances R. Levin, Muredach P. Reilly, Nabila El-Bassel
56 [GO] 2020―Nov―04 COVID-19 highlights the pitfalls of reliance on the carceral system as a response to addiction Melissa J. Zielinski, Kendra E. Hinton, Chelsey E. Bull
57 [GO] 2020―Oct―21 “I have to be around people that are doing what I’m doing”: The importance of expanding the peer recovery coach role in treatment of opioid use disorder in the face of COVID-19 health disparities Mary B. Kleinman, Julia W. Felton, Andre Johnson, Jessica F. Magidson
58 [GO] 2020―Oct―21 COVID-19 innovations in medication for addiction treatment at a Skid Row syringe exchange Rolando Tringale, Andrew M. Subica
59 [GO] 2020―Oct―21 A commentary on the impact of COVID-19 on engagement of youth with substance use and co-occurring psychiatric disorders Sarah M. Bagley, Scott E. Hadland, Amy Yule
60 [GO] 2020―Oct―21 Healthcare Utilization Patterns among Persons Who Use Drugs During the COVID-19 Pandemic Sean M. Murphy, James Yoder, Jyotishman Pathak, Jonathan Avery
61 [GO] 2020―Oct―21 COVID-19-related treatment service disruptions among people with single- and polysubstance use concerns Alexandra M. Mellis, Marc N. Potenza, Jessica N. Hulsey
62 [GO] 2020―Oct―10 Rapid Transitional Reponse to the COVID-19 Pandemic by Opioid Agonist Treatment Programs in Ukraine Anna Meteliuk, Samy Galvez, Lynn M. Madden, Iryna Pykalo, Tanya Fomenko, Myroslava Fillipovich, et al. (+4)
63 [GO] 2020―Oct―09 Virtual reality for behavioral health workforce development in the era of COVID-19 Sara Becker, Michael Chaple, Tom Freese, Holly Hagle, Maxine Henry, Igor Koutsenok, et al. (+8)
64 [GO] 2020―Oct―09 The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19 Jaclyn M.W. Hughto, Lisa Peterson, Nicholas S. Perry, Alex Donoyan, Matthew J. Mimiaga, Kimberly M. Nelson, David W. Pantalone
65 [GO] 2020―Oct―09 Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada Dennis C. Wendt, Stéphanie Marsan, Daniel Parker, Karen E. Lizzy, Jessica Roper, Christopher Mushquash, et al. (+9)
66 [GO] 2020―Oct―08 Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic Alexandra Duncan, Noah Sanders, Maria Schiff, Tyler N.A. Winkelman
67 [GO] 2020―Oct―06 A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose Benjamin P. Linas, Alexandra Savinkina, Carolina Barbosa, Peter P. Mueller, Magdalena Cerdá, Katherine Keyes, Jagpreet Chhatwal
68 [GO] 2020―Oct―05 Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic Jarratt D. Pytell, Darius A. Rastegar
69 [GO] 2020―Oct―04 Online digital recovery support services: An overview of the science and their potential to help individuals with substance use disorder during COVID-19 and beyond Brandon G. Bergman, John F. Kelly
70 [GO] 2020―Oct―04 Considerations for remote delivery of behavioral economic interventions for substance use disorder during COVID-19 and beyond Lara N. Coughlin, Erin E. Bonar, Warren K. Bickel
71 [GO] 2020―Oct―04 COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings Laura MacKinnon, M. Eugenia Socías, Geoff Bardwell
72 [GO] 2020―Oct―03 Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care? Joan Trujols, Antonio Larrabeiti, Oriol Sànchez, Maite Madrid, Sandra De Andrés, Santiago Duran-Sindreu
73 [GO] 2020―Oct―02 Providing addiction services during a pandemic: Lessons learned from COVID-19 Bruce S. Liese, Corey M. Monley
74 [GO] 2020―Sep―25 Substance use disorder treatment, parenting, and COVID-19 Camille C. Cioffi, Leslie D. Leve
75 [GO] 2020―Sep―25 Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency Kevin Wenzel, Marc Fishman
76 [GO] 2020―Sep―25 Access to Substance Use Disorder Treatment During COVID-19: Implications from Reduced Local Jail Populations Erkmen G. Aslim, Murat C. Mungan
77 [GO] 2020―Sep―21 COVID-19: Revising our attitudes toward agonist medications and their diversion Brandon del Pozo, Josiah D. Rich
78 [GO] 2020―Sep―18 Treatment experience for opioid use disorder during COVID-19 in India: Learning from patients Prabhat Mani Pandit, Gayatri Bhatia, Siddharth Sarkar
79 [GO] 2020―Aug―30 Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine Lori Uscher-Pines, Jessica Sousa, Pushpa Raja, Ateev Mehrotra, Michael Barnett, Haiden A. Huskamp
80 [GO] 2020―Aug―12 Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities Simeon D. Kimmel, Angela R. Bazzi, Joshua A. Barocas
81 [GO] 2020―Aug―11 Adaptation of Contingency Management for Stimulant Use Disorder During the COVID-19 Pandemic Evelyn Zastepa, Jane C. Sun, Jennifer Clune, Nickie Mathew
82 [GO] 2020―Aug―05 Making lemonade from SARS coronavirus-2 lemons: Transitioning a smoking cessation trial to a virtual platform Martin C. Mahoney, Rebecca Ashare, Nicolas Schlienz, CeCe Duerr, Larry W. Hawk
83 [GO] 2020―Aug―01 Sheltering in place and social distancing when the services provided are housing and social support: The COVID-19 health crisis and recovery housing Amy A. Mericle, Dave Sheridan, Jason Howell, George S. Braucht, Katherine Karriker-Jaffe, Douglas L. Polcin
84 [GO] 2020―Jul―25 Editorial: COVID-19 and its impact on SUD treatment Peter D. Friedmann, Amanda Abraham, Elizabeth Evans, Joseph Glass, Mark Ilgen, LaTrice Montgomery
85 [GO] 2020―May―07 Call for commentaries on COVID-19


Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.006 sec